Topical delivery of imiquimod to a mouse model as a novel adjuvant for human immunodeficiency virus (HIV) DNA

We evaluated the compound imiquimod as a possible adjuvant for DNA immunization against human immunodeficiency virus (HIV). We found that gene-gun epidermal delivery of the DNA in combination with imiquimod resulted in the strongest HIV specific immune responses. The effect of imiquimod was further...

Full description

Saved in:
Bibliographic Details
Published in:Vaccine 2004-04, Vol.22 (13), p.1791-1798
Main Authors: Zuber, Anne Kjerrström, Bråve, Andreas, Engström, Gunnel, Zuber, Bartek, Ljungberg, Karl, Fredriksson, Malin, Benthin, Reinhold, Isaguliants, Maria G, Sandström, Eric, Hinkula, Jorma, Wahren, Britta
Format: Article
Language:English
Subjects:
Adjuvants, Immunologic - administration & dosage
Adjuvants, Immunologic - pharmacology
Administration, Topical
AIDS Vaccines - immunology
Aminoquinolines - administration & dosage
Aminoquinolines - pharmacology
Animals
Antibody Formation - immunology
Biolistics
Cell growth
Cytokines - biosynthesis
Cytokines - blood
Deoxyribonucleic acid
DNA
DNA vaccination
Enzyme-Linked Immunosorbent Assay
Enzymes
Genes
GM-CSF
Granulocyte-Macrophage Colony-Stimulating Factor - immunology
HIV
HIV-1
HIV-1 - genetics
HIV-1 - immunology
Human immunodeficiency virus
Imiquimod
Immune system
Immunity, Cellular - immunology
Immunization
Injections, Intradermal
Interferon-gamma - analysis
Interferon-gamma - biosynthesis
Leukemia
Leukemia Virus, Murine - immunology
Medicin och hälsovetenskap
Mice
Plasmids
Proteins
R&D
Research & development
Spleen - cytology
Spleen - immunology
Vaccines
Vaccines, DNA - immunology
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:We evaluated the compound imiquimod as a possible adjuvant for DNA immunization against human immunodeficiency virus (HIV). We found that gene-gun epidermal delivery of the DNA in combination with imiquimod resulted in the strongest HIV specific immune responses. The effect of imiquimod was further compared to that of recombinant granulocyte macrophage-colony stimulating factor (GM-CSF), a known DNA vaccine adjuvant. Both adjuvants were able to enhance the immune responses induced by the HIV-1 genes alone. The delivery of an adjuvant as a topical cream rather than through injections has a clear clinical benefit. We show for the first time that imiquimod can act as an adjuvant for DNA vaccination.
ISSN:0264-410X
1873-2518
DOI:10.1016/j.vaccine.2003.10.051